A bacterium with unusually strong antitumor activity has turned up in the gut of the Japanese tree frog, a small green amphibian common in rice paddies and gardens across Japan.

Seigo Iwata and Professor Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST) showed that Ewingella americana, isolated from tree frog intestines, completely eliminated colorectal tumors in mice after a single injection. The work was published in Gut Microbes on December 10, 2025.

One thing to establish up front: this is preclinical work in mice. No human trial has begun.

Why Amphibians Caught Scientists' Attention

Have you ever heard of a frog or lizard getting cancer? Probably not. This isn't simply because we don't observe these animals closely enough. In fact, biologists have long noted that spontaneous tumors are remarkably rare in wild amphibians, a mystery that has puzzled scientists for years.

With recent advances revealing the profound influence of gut bacteria on immune function and cancer progression, the research team hypothesized that the unique gut microbiome of amphibians might harbor cancer-fighting secrets.

Finding a "Super Bacterium" Among 45 Strains

The research team collected gut bacteria from three species of amphibians and reptiles native to Japan. Their subjects included the Japanese tree frog (Dryophytes japonicus), the Japanese fire belly newt (Cynops pyrrhogaster), and the Japanese grass lizard (Takydromus tachydromoides).

From these animals they isolated 45 bacterial strains and screened them systematically for safety and antitumor effect. Nine made it through: five significantly slowed tumor growth, and three produced both slowed growth and tumor regression. One stood out from the rest, Ewingella americana from the Japanese tree frog.

A 100% Complete Response Rate After One Dose

In a mouse colorectal cancer model, a single intravenous dose of E. americana cleared tumors entirely, a 100% complete response (CR) rate. That is well beyond what current standard treatments managed in the same comparison, including an immune checkpoint inhibitor (anti-PD-L1 antibody) and chemotherapy (liposomal doxorubicin). The model used tumor cells implanted subcutaneously; an orthotopic model, with tumors grown in the colon itself, has yet to be tested.

In comparative trials, chemotherapy and immunotherapy showed only partial effectiveness in some mice. In contrast, every single mouse in the bacterial treatment group saw their tumors completely disappear.

The effect also held. When researchers re-implanted cancer cells in the cured mice 30 days later, the tumors did not grow, which points to immunological memory having formed.

A Dual-Action Attack Mechanism

The exceptional anticancer effect of E. americana stems from its unique two-pronged attack mechanism.

Direct Cytotoxic Effect

This bacterium is a facultative anaerobe: it can survive in oxygen but thrives in low-oxygen environments. The core of solid tumors is typically hypoxic, creating a fortress that many anticancer drugs struggle to penetrate. For E. americana, however, this oxygen-starved environment is the perfect habitat.

Within 24 hours of administration, bacterial counts within tumors increased approximately 3,000-fold. This explosive growth enables direct destruction of cancer cells.

Immune Activation Effect

The bacterial presence powerfully stimulates the immune system, recruiting T cells, B cells, and neutrophils to the tumor site. These immune cells produce pro-inflammatory cytokines (TNF-α, IFN-γ) that further amplify immune responses and induce cancer cell apoptosis.

This combination of "direct attack" and "immune activation" produces effects that far exceed conventional treatments.

Precision Targeting: Tumors Only

E. americana accumulated selectively in tumor tissue and colonized no normal organs. The paper attributes that to conditions specific to tumors: hypoxia inside the tumor favors anaerobic growth, CD47 expressed by cancer cells creates local immunosuppression that lets the bacteria survive, the leaky abnormal vasculature of tumor tissue lets them in, and tumor-specific metabolites feed them once they arrive.

Safety Findings in Mice

The bacterium's blood half-life was roughly 1.2 hours, and it was undetectable after 24. No colonization appeared in the liver, spleen, lungs, kidneys, or heart. Inflammation was transient and mild, resolving within 72 hours, and 60 days of observation turned up no chronic toxicity.

Importantly, the bacterium is sensitive to standard antibiotics, providing a safety "kill switch" if any problems arise during treatment.

The bacterium is not, however, unknown to human medicine. Ewingella americana was described as a new genus and species in 1983, is commonly found on vegetables and mushrooms, and has accumulated case reports as an opportunistic human pathogen: bacteraemia, pneumonia, conjunctivitis, peritonitis and catheter-associated urinary tract infection. In June 2025, Cureus reported sepsis in a cancer patient undergoing chemotherapy who received a red blood cell transfusion. A 2024 report described a multidrug-resistant isolate susceptible only to tigecycline.

None of this contradicts the paper's findings, but it matters for any clinical path. The patients this therapy would target are people with refractory cancer, which is to say immunocompromised people, the same group in which those infections have been reported. Safety in mice and safety in an immunosuppressed human are separate questions.

Future Prospects and Challenges

The team plans to test breast, pancreatic, and melanoma models next, to optimize delivery through dose fractionation and intratumoral injection, and to look for synergy with existing immunotherapy and chemotherapy. The paper flags hypoxic, immunologically "cold" tumors, pancreatic and triple-negative breast cancer among them, as promising candidates.

To repeat the caveat, though: these are mouse results. Human application will require further safety work, dose-finding, and a clearer mechanistic picture of how the bacteria reach tumors, and no trial has been scheduled. Anyone weighing cancer treatment options should talk to their oncologist.

Biodiversity: A Treasury of Medical Innovation

Professor Miyako stated, "This research demonstrates that unexplored biodiversity represents a treasure trove for new medical technology development, while potentially providing new treatment options for patients with refractory cancers."

A lead on cancer treatment was sitting in the gut of a common frog, which says something about how much of the natural world remains unexamined.

What about your country? Is research on gut bacteria or microbiome-based cancer treatments advancing? Have there been any discoveries of medical applications from common animals in your region? We'd love to hear your thoughts!

References